{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-015343","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.769285+00:00","generated_at":"2026-06-16T09:03:14.801206+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Soticlestat long-term OLE data shows sustained seizure reduction in Dravet and LGS","bullets":["ENDYMION 1 interim analysis: soticlestat generally safe and well tolerated over ~2 years; 78% tolerated 300 mg BID.","Dravet patients: median convulsive seizure reduction -33.7% (wk1-12), -47.8% (wk49-60), -58.2% (wk97-108).","LGS patients: median drop seizure reduction -29.3% (wk1-12), -14.1% (wk49-60), -36.6% (wk97-108).","Post-hoc ELEKTRA analysis: soticlestat showed numerically superior reduction vs placebo across most seizure types.","Ovid maintains significant financial interest in soticlestat (milestones and royalties from Takeda)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-015343","json":"https://secwatch.observer/filing/0000950170-23-015343.json","markdown":"https://secwatch.observer/filing/0000950170-23-015343.md","text":"https://secwatch.observer/filing/0000950170-23-015343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023015343/0000950170-23-015343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023015343/ovid-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T09:03:14.801206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}